Maserati R - Search Results

1

Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.

Seminari E, Lisziewicz J, Tinelli C, Foli A, Lori F, Maserati R. Seminari E, et al. Among authors: maserati r. Int J Clin Pharmacol Ther. 1999 Oct;37(10):514-8. Int J Clin Pharmacol Ther. 1999. PMID: 10543320 Clinical Trial.

2

Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.

Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J. Lori F, et al. Among authors: maserati r. AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1333-8. doi: 10.1089/088922299310034. AIDS Res Hum Retroviruses. 1999. PMID: 10515148

3

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.

Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J. Foli A, et al. Among authors: maserati r. Antivir Ther. 1997 Jan;2(1):31-8. Antivir Ther. 1997. PMID: 11322264 Clinical Trial.

4

Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I.

Villani P, Maserati R, Regazzi MB, Giacchino R, Lori F. Villani P, et al. Among authors: maserati r. J Clin Pharmacol. 1996 Feb;36(2):117-21. doi: 10.1002/j.1552-4604.1996.tb04176.x. J Clin Pharmacol. 1996. PMID: 8852387 Clinical Trial.

5

[Clinical significance of diplopia in HIV infection. Assessment of a personal caseload and review of the literature].

Seminari E, Cocchi L, Antoniazzi E, Giacchino R, Maserati R. Seminari E, et al. Among authors: maserati r. Minerva Med. 1996 Nov;87(11):515-23. Minerva Med. 1996. PMID: 9045102 Review. Italian.

6

Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.

Foli A, Maserati R, Minoli L, Wainberg MA, Gallo RC, Lisziewicz J, Lori F. Foli A, et al. Among authors: maserati r. AIDS. 1998 Jun 18;12(9):1113-4. AIDS. 1998. PMID: 9662215 No abstract available.

7

Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.

Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R. Villani P, et al. Among authors: maserati r. Br J Clin Pharmacol. 1999 Nov;48(5):712-5. doi: 10.1046/j.1365-2125.1999.00071.x. Br J Clin Pharmacol. 1999. PMID: 10594473 Free PMC article. Clinical Trial.

8

Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.

Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C. Regazzi MB, et al. Among authors: maserati r. J Antimicrob Chemother. 2000 Mar;45(3):343-7. doi: 10.1093/jac/45.3.343. J Antimicrob Chemother. 2000. PMID: 10702554 Clinical Trial.

9

Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.

Seminari E, Maggiolo F, Villani P, Suter F, Pan A, Regazzi MB, Paolucci S, Baldanti F, Tinelli C, Maserati R. Seminari E, et al. Among authors: maserati r. J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):453-60. doi: 10.1097/00126334-199912150-00005. J Acquir Immune Defic Syndr. 1999. PMID: 10961606 Clinical Trial.

10

Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.

Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, Minoli L, Meneghetti G, Tinelli C, Testa S. Seminari E, et al. Among authors: maserati r. Atherosclerosis. 2002 Jun;162(2):433-8. doi: 10.1016/s0021-9150(01)00736-5. Atherosclerosis. 2002. PMID: 11996964

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters